❌

Reading view

There are new articles available, click to refresh the page.

FDA Panel Rejects Use of MDMA for Treatment of PTSD

An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.

Β© Travis Dove for The New York Times

A dose of MDMA from the MAPS Public Benefit Corp., which is now renamed as Lykos Therapeutics, a for-profit company whose studies the F.D.A. is analyzing.

In the House of Psychiatry, a Jarring Tale of Violence

At the American Psychiatric Association’s annual meeting, a patient described a restraint that haunts him, more than eight years later.

Β© Diana Cervantes for The New York Times

Matthew Tuleja, a former college football player, hopes that sharing his story will help reduce the use of restraints in psychiatry.
❌